Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This educational activity is supported by educational grants from AstraZeneca, Foundation Medicine, GRAIL, Guardant Health, and Eli Lilly.

For further information concerning Lilly grant funding, visit

Community Practice Connections™: Medical Crossfire®: Novel Applications of Liquid Biopsies Across Cancer Care

Release Date: August 30, 2020
Expiration Date: August 30, 2021

Activity Overview

The advent of improved sequencing technologies and platforms has rapidly expanded the understanding of genomic alterations that drive tumor biology. Accordingly, in recent decades numerous targeted agents for individual alterations have been introduced as treatment options across solid tumors, and there are many more agents in ongoing clinical trials. Clinicians treating patients with solid tumors, especially lung, breast, and gastrointestinal malignancies, are faced with the challenge of determining how and when to perform molecular testing on their patients and how to use that information to optimize treatment planning.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from the live, virtual Medical Crossfire®: Novel Applications of Liquid Biopsies Across Cancer Care, held in June 2020. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of applying liquid biopsy to the management of patients with solid tumors, putting recent clinical trial data into clinical context. The program is designed to provide information to clinicians who did not attend the live meeting and to help reinforce learnings for those who did attend.

Acknowledgment of Commercial Support

This educational activity is supported by educational grants from AstraZeneca, Foundation Medicine, GRAIL, Guardant Health, and Eli Lilly.

For further information concerning Lilly grant funding, visit


Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of cancer. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Summarize the comparative advantages of currently available liquid-based and tissue-based testing approaches
  • Evaluate clinical data concerning new and emerging liquid biopsy technologies
  • Describe emerging uses of liquid biopsies across the spectrum of cancer care, including in non–small cell lung cancer, breast cancer, and gastrointestinal cancers
  • Assess clinical evidence pertaining to specific testing modalities that may help to individualize treatment protocols for patients with cancer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Ian E. Krop, MD, PhD
Charu Aggarwal, MD, MPH
Leslye M. Heisler Assistant Professor for Lung Cancer Excellence
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA

Disclosures: Grant Research Support: AstraZeneca, Celgene, Eli Lilly, Merck, Roche.

Ian E. Krop, MD, PhD
Aditya Bardia, MD, MPH
Director, Precision Medicine, Center for Breast Cancer
Assistant Professor of Medicine, Harvard Medical School
Attending Physician, Medical Oncology, Massachusetts General Hospital
Boston, MA

Disclosures: Grant Research Support: Genentech/Roche (institution), Immunomedics (institution), Novartis (institution), Pfizer (institution), Merck (institution), Radius Health (institution), Sanofi (institution), Mersana Therapeutics (institution), Daiichi Sankyo/AstraZeneca (institution); Consultant: Genentech/Roche, Immunomedics, Novartis, Pfizer, Merck, Radius Health, Sanofi, Daiichi Sankyo/AstraZeneca (institution).

Ian E. Krop, MD, PhD
Ryan B. Corcoran, MD, PhD
Director, Gastrointestinal Cancer Center Program
Massachusetts General Hospital Cancer Center
Boston, MA

Disclosures: Grant Research Support: Asana BioSciences, Lilly; Consultant: Array BioPharma, Astex, Avidity Biosciences, C4 Therapeutics, Elicio Therapeutics, Kinnate Biopharma, Ipsen, Natera, N-of-One/QIAGEN, nRichDX, Revolution Medicines, Roivant Sciences, Taiho Pharmaceutical, Zikani Therapeutics; Other: Avidity Biosciences, C4 Therapeutics, Kinnate Biopharma, nRichDX, Revolution Medicines.

Ian E. Krop, MD, PhD
Benjamin P. Levy, MD
Associate Professor of Oncology, Johns Hopkins University School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Sibley Memorial Hospital
Washington, DC

Disclosures: Grant Research Support: Turning Point Therapeutics, AstraZeneca, Eli Lilly, Genentech Roche; Consultant: AstraZeneca, Merck, Eli Lilly, Novartis, Pfizer, Genentech Roche, Guardant Health.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By